Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Leap Therapeutics Inc
LPTX | US
2.98
USD0.30
11.40%
LPTX | US
About Leap Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.98
Open
2.68
High
3.00
Low
2.53
Leap Therapeutics Inc. a biopharmaceutical company acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01 a monoclonal antibody that inhibits Dickkopf-related protein 1 which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301 a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial as well as two preclinical antibody programs FL-302 and FL-501. Leap Therapeutics Inc. has an option and license agreement with BeiGene Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan) Australia and New Zealand. The company was formerly known as HealthCare Pharmaceuticals Inc. and changed its name to Leap Therapeutics Inc. in November 2015. Leap Therapeutics Inc. was incorporated in 2011 and is based in Cambridge Massachusetts.
View LessLPTX | US
Risk
85.8
Sharpe
0.89
Luna's Score
60/100
Recommendation
Hold
Luna says (LPTX | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
102.3%1 month
85.8%3 months
78.2%6 months
77.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.36
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.47
Ent. to rev.
1.90
PEG
0.75
Other Fundamentals
EBITDA
-64.69M
MarketCap
114.03M
MarketCap(USD)
114.03M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-80.54
Short ratio
6.71
Short perc.
2.79
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.80
Range1M
0.80
Range3M
1.46
Volumes: Market Activity
Rel. volume
1.78
Price X volume
1.10M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.47 | - | Par |
| Ent. to Revenue | 1.90 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.36 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 78.24 | - | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 114.03M | - | Emerging |
